Xeris Pharmaceuticals shares latest product and partnership updates

Xeris Pharmaceuticals chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product line performance.

Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a proven therapy for primary periodic paralysis; and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol and XeriJect, to support long-term product development and commercial success.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com